UNSPSC 51141575: Ralitoline

This classification denotes an anticonvulsant agent with the molecular formula C13H13ClN2O2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Q4MW9RM93A, chemically known as (z)-6-chloro-3-methyl-4-oxo-delta(sup 2,alpha)-thiazolidineaceto-o-toludide but generally known as ralitoline, which bears US NIH Compound Identifier 6436118. European Medicines Agency schedules Ralitoline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10242MIG. The term RALITOLINE is an International Non-Proprietary Name.

UNSPSC 51141575 Ralitoline is a Commodity code that covers pharmaceutical products and related health-supply procurement by state and local governments. However, the recent opportunities tagged under this code show significant mismatch with the nominal product category. Seminole County, Florida is procuring naloxone and drug deactivation systems through an IFB (invitation for bid); the Texas Health and Human Services Commission issued an RFI for direct-to-manufacturer prescription program capabilities; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP for generic multi-source pharmaceuticals and over-the-counter products. None of these solicitations explicitly reference ralitoline, and the actual work being bought spans emergency-response medications, pharmacy benefit program infrastructure, and generic pharmaceutical supply chains—categories that diverge materially from the code's nominal scope. The issuing bodies include county health departments, state health agencies, and cooperative purchasing alliances serving multiple state and local jurisdictions.

Activity under this code spans Florida, Texas, and Minnesota, with MMCAP's multi-state cooperative structure extending reach to Oregon and other participating jurisdictions. Seminole County's naloxone and drug deactivation systems contract (IFB 60459723LAS, due July 26, 2023) requires quarterly delivery of 1,900 units of naloxone and 800 deactivation systems annually to its community health building in Sanford, with a two-year initial term and one-year renewal option. The Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) solicited vendor capabilities for direct-to-manufacturer prescription programs without a formal evaluation timeline or award value. MMCAP's pharmaceutical RFP (S1070000015802, due March 26, 2026) targets generic drugs and OTC products distributed through three authorized wholesalers, with contract effectiveness July 1, 2026, and evaluation weighted 75 percent on price competitiveness. The mismatch between the code designation and actual solicitation content suggests either miscoding of opportunities or that ralitoline is not a primary focus of current state and local procurement activity.